1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

"UCB S.A.: PharmaVitae Profile" is now available at Fast Market Research

Recently published research from Datamonitor, "UCB S.A.: PharmaVitae Profile", is now available at Fast Market Research

 
PRLog - May 20, 2011 - Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into UCB's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for UCB over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158625_ucb_sa_pharmavitae_prof...
------------------------------------------------------------

* Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector* Examine the long-term sales potential of the monoclonal antibody Cimzia; providing a route to diversify its  molecule type and therapy area offering


Report Table of Contents:

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-
Financial performance, 2003-
UCB: PharmaVitae forecasts at a glance
Strategic insight
Biopharmaceutical business model key to UCB's future sales growth
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest comment
Q2
UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential
Latest prescription pharma product news
Q4
Q3
Q2
Latest corporate news
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Celltech
Schwarz Pharma
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-
Product analysis
Product analysis, 2003-
Product analysis, 2009-
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Generics analysis, 2009-
Launch/core/expiry configuration, 2009-
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-
Operating costs and profit analysis
Operating costs and profit analysis, 2003-
Operating cost ratio and profit margin analysis, 2003-
Operating cost ratio and profit margin analysis, 2009-
Operating costs and profit analysis, 2009-
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Central nervous system
Keppra/Keppra XR
Rikelta
Neupro
Vimpat
Immunology & inflammation
Cimzia
APPENDIX
References
Abbreviations
Exchange rates

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical, Research, Biotech
Tags:ucb, prescription, pharmaceutical, pharma, pharmavitae, molecule, therapy, cimzia, vimpat
Shortcut:prlog.org/11500705
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share